Although Chagas disease was only discovered in 1909, it began millions of years ago
as an enzootic disease among wild animals. Its transmission to man began accidentally
as an anthropozoonosis when mankind invaded wild ecotopes. Endemic Chagas disease
became established as a zoonosis over the last 200-300 years through deforestation
for agriculture and livestock rearing and adaptation of triatomines to dwellings and
to humans and domestic animals as food sources. When T. cruzi is transmitted to man,
it invades the bloodstream and lymphatic system and lodges in muscle and heart tissue,
the digestive system and phagocytic cells. Through this, it causes inflammatory lesions
and an immune response, particularly mediated by CD4(+), CD8(+), IL2 and IL4, with
cell and neuron destruction and fibrosis. These processes lead to blockage of the
heart's conductive system, arrhythmias, heart failure, aperistalsis and dilatation
of hollow viscera, especially the esophagus and colons. Chagas disease is characterized
by an acute phase with or without symptoms, with (or more often without) T. cruzi
penetration signs (inoculation chagoma or Romaña's sign), fever, adenomegaly, hepatosplenomegaly
and patent parasitemia; and a chronic phase: indeterminate (asymptomatic, with normal
electrocardiogram and heart, esophagus and colon X-rays) or cardiac, digestive or
cardiac/digestive forms. There is great regional variation in the morbidity caused
by Chagas disease: severe cardiac or digestive forms may occur in 10-50%, and indeterminate
forms in the remaining, asymptomatic cases. The epidemiological and control characteristics
of Chagas disease vary according to each country's ecological conditions and health
policies.
2010. Published by Elsevier B.V.